China Biotech Services Holdings Ltd

China Biotech Services Holdings Ltd

  • Price (HKD)1.24
  • Today's Change0.04 / 3.33%
  • Shares traded245.00k
  • 1 Year change-21.52%
  • Beta--
Data delayed at least 15 minutes, as of Aug 16 2022 08:59 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

China Biotech Services Holdings Limited, formerly Rui Kang Pharmaceutical Group Investments Limited is a Hong Kong-based investment holding company principally engaged in the trading of securities. The Company is also engaged in the manufacture, research and development, sales and distribution of consumer cosmetics, health related and pharmaceutical products, health supplement wine, dental materials and equipment in the People’s Republic of China (the PRC) and Hong Kong, as well as the provision of medical laboratory testing services and health check services in Hong Kong. The Company is also involved in the property holding and money lending businesses through its subsidiaries.

  • Revenue in HKD (TTM)853.68m
  • Net income in HKD52.50m
  • Incorporated2016
  • Employees211.00
  • Location
    China Biotech Services Holdings LtdRoom 1213, Tower A, New Mandarin Plaza14 Science Museum RoadKowloon Hong KongHKG
  • Phone+852 31883333
  • Fax+852 21513968
  • Websitehttp://www.cbshhk.com/
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.